Respiratory medicine最新文献

{"title":"Diaphragm Ultrasound-Guided PEEP Titration in COPD with Dynamic Hyperinflation.","authors":"Paula Quiñones, Patrick Sepúlveda, Ricardo Arriagada, Elisa Cappuccio, Patricia R M Rocco, Denise Battaglini","doi":"10.1016/j.rmed.2026.109238","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.109238","url":null,"abstract":"<p><p>Chronic obstructive pulmonary disease (COPD) is characterized by airflow limitation, dynamic hyperinflation, and intrinsic positive end-expiratory pressure (iPEEP), which increase inspiratory threshold load and complicate ventilatory support. Non-invasive ventilation (NIV) is the preferred initial ventilatory support for COPD exacerbations complicated by acute or acute-on-chronic respiratory acidosis, while invasive mechanical ventilation (IMV) may be required when NIV fails. External PEEP may reduce the inspiratory threshold load in patients with expiratory flow limitation, although excessive levels can increase lung volume and compromise hemodynamics. During IMV, PEEP adjustment requires assessment of respiratory mechanics, expiratory flow, hyperinflation, and cardiovascular tolerance. During NIV, where iPEEP cannot usually be measured directly, expiratory positive airway pressure (EPAP) should be adjusted according to clinical response, patient-ventilator interaction, and signs of excessive lung inflation. Inappropriate ventilatory assistance may also contribute to diaphragm dysfunction. Diaphragm ultrasound allows bedside assessment of muscle thickness and inspiratory thickening fraction (DTF), although these measurements are influenced by ventilatory assistance, respiratory drive, and lung volume. This review examines the physiological basis, available evidence, and limitations of using diaphragm ultrasound to complement PEEP adjustment in patients with COPD and dynamic hyperinflation. No DTF target or clinical benefit of ultrasound-guided PEEP titration has been established in this population.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109238"},"PeriodicalIF":3.3,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Foot-to-foot lower-limb phase angle as a predictor of reduced exercise capacity in patients with interstitial lung disease: A comparative study with muscle mass and pulmonary function.","authors":"Kento Kaneko, Masahiro Ishizaka, Tsuyoshi Hara, Kohei Chiba, Kenya Takei, Fumiaki Ishikawa, Keita Sakamoto, Nobuyasu Awano, Minoru Inomata, Hitomi Takahashi, Takehiro Izumo","doi":"10.1016/j.rmed.2026.109236","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.109236","url":null,"abstract":"<p><strong>Background: </strong>Reduced exercise capacity, measured by the 6-min walk distance (6MWD), is a critical prognostic factor in interstitial lung disease (ILD). However, conventional physiological markers often fail to identify early functional decline. We aimed to evaluate whether the foot-to-foot lower-limb phase angle (F-F PhA), a non-invasive surrogate marker of muscle quality, predicts reduced exercise capacity better than traditional muscle mass and pulmonary function indices.</p><p><strong>Methods: </strong>In this retrospective study of 68 patients with ILD, F-F PhA was measured using bioelectrical impedance analysis, and erector spinae muscle area (ESM_CSA) via computed tomography. Reduced exercise capacity was defined as 6MWD < 450 m. Multivariable logistic regression models adjusted for age and pulmonary function (%DL_CO or %FVC), with internal validation performed via 1000-resample bootstrapping.</p><p><strong>Results: </strong>In multivariable analysis, F-F PhA was independently associated with a 6MWD < 450 m when adjusted for age and %DL_CO (OR: 0.228, 95% CI: 0.088-0.591, p = 0.002; bootstrap p = 0.005) or %FVC (OR: 0.213, 95% CI: 0.091-0.496, p = 0.001; bootstrap p = 0.001). ROC analysis showed F-F PhA had the highest discriminative accuracy (AUC: 0.802), outperforming %DL_CO (AUC: 0.729) and ESM_CSA (AUC: 0.701). Combining age, %DL_CO, and F-F PhA achieved the highest performance (AUC: 0.833).</p><p><strong>Conclusions: </strong>F-F PhA serves as a robust, independent indicator for predicting reduced exercise capacity in ILD, outperforming conventional muscle mass. As a non-invasive tool, F-F PhA complements established functional tests in screening for early physical decline.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"264 ","pages":"109236"},"PeriodicalIF":3.3,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228598","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apnea-hypopnea index-oxygen desaturation index (AHI-ODI) discordance in obstructive sleep apnea: association with symptom burden and cardiometabolic comorbidity: A retrospective cross-sectional study.","authors":"Ahmed Ehab, Heba Wagih Abdelwahab, Mohamed Hamoda, Mahmoud M Elhosiny","doi":"10.1016/j.rmed.2026.109237","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.109237","url":null,"abstract":"<p><strong>Background: </strong>The apnea-hypopnea index (AHI) counts respiratory events but not the depth or duration of accompanying desaturation. We examined AHI-ODI discordance (AHI minus oxygen desaturation index, ODI) and its associations with daytime symptom burden and prevalent cardiometabolic comorbidity.</p><p><strong>Methods: </strong>Single-center retrospective cross-sectional study of 200 adults with OSA (January 2023-January 2025). Five indices (AHI, ODI, mean SpO₂, T90 and AHI-ODI discordance) were examined; excessive daytime sleepiness (EDS; Epworth Sleepiness Scale ≥ 11) was the primary outcome. Multivariable logistic regression adjusted for age, sex, BMI and an AHI-ODI × sex interaction.</p><p><strong>Results: </strong>The cohort was 77.5% male, median age 57 years (48.8-64.2). For EDS, AHI-ODI discordance showed the numerically highest AUC (0.639, p < 0.001), followed by T90 (0.627), and mean SpO₂ and ODI (0.609 each); AHI was not significant (0.546, p = 0.264). No pairwise difference was significant. AHI-ODI discordance remained independently associated with EDS after adjustment (OR 1.04 per event/h, 95% CI 1.01-1.07, p = 0.008), with no significant sex interaction. Among secondary outcomes, T90 showed the highest AUCs for diabetes mellitus (0.644) and hypertension (0.615), and mean SpO₂ for heart failure (0.608). No index discriminated against previous stroke or atrial fibrillation.</p><p><strong>Conclusions: </strong>AHI-ODI discordance was independently, but only modestly, associated with EDS, whereas oxygenation indices were related to prevalent cardiometabolic comorbidity. The discrimination was insufficient, and all reported cut-offs are exploratory. AHI-ODI discordance is not a measure of sleep apnea-specific hypoxic burden.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":"264 ","pages":"109237"},"PeriodicalIF":3.3,"publicationDate":"2026-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149228609","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The association between New Zealand Blackcurrant anthocyanins and airway inflammation, including PAI-1, in asthma: A placebo-controlled crossover feasibility study.","authors":"Madiha Ajaz, Indu Singh, Lada Vugic, Rati Jani, Maninder P Singh, Natalie Shilton","doi":"10.1016/j.rmed.2026.109222","DOIUrl":"10.1016/j.rmed.2026.109222","url":null,"abstract":"<p><p>Asthma is a common chronic inflammatory airway disease. Plasminogen activator inhibitor 1 (PAI-1) contributes to airway inflammation, remodelling, disease severity, and exacerbations. As anthocyanins (ACN) possess antioxidant and anti-inflammatory properties, and oxidative stress is a key feature of asthma, investigating the efficacy of anthocyanin supplementation in this population is warranted. Although the study was originally designed to assess variability to plan a larger study in the event only five participants were recruited. The study design was a cross-over design. Participants received either a 300 mg ACN supplement or an identical placebo for eight weeks. Feasibility outcomes and asthma symptom control were assessed, alongside exploratory analyses of inflammatory markers, including fractional exhaled nitric oxide (FeNO) and salivary plasminogen activator inhibitor-1 (PAI-1). Associations between changes in PAI-1, Dietary Inflammatory Index (DII) scores, and the PAI-1 4G/5G polymorphism were also explored. Improvements in asthma symptom control were observed following ACN supplementation, including reduced daytime and nighttime symptoms and no activity limitation, similar to the placebo phase. Moreover, an absence of short-acting beta-agonist (SABA) reliever use N/N 0/5, 0%; SABA use reappeared during the placebo phase N/N 1/5, 20%. Preliminary findings support the feasibility of conducting a larger trial of ACN supplementation in adults with asthma. While ACN supplementation may have a positive effect on asthma symptom control, the findings are exploratory and require confirmation in adequately powered studies with larger sample sizes.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109222"},"PeriodicalIF":3.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bedside flexible bronchoscopy in the neonatal intensive care unit: Current evidence, clinical applications and future directions.","authors":"Adil Ahmed Khan, Fajia Farhath, Ravneet Kaur Saluja","doi":"10.1016/j.rmed.2026.109224","DOIUrl":"10.1016/j.rmed.2026.109224","url":null,"abstract":"<p><strong>Background: </strong>Lung ultrasound and targeted echocardiography let the neonatal team examine lungs and heart at the cot side, but neither shows the airway. Flexible bronchoscopy does, and it is increasingly performed inside the neonatal intensive care unit (NICU).</p><p><strong>Methods: </strong>Narrative review of published series of flexible bronchoscopy in infants cared for in neonatal units, supported by pediatric intensive care studies and society standards. Certainty of evidence was not graded.</p><p><strong>Results: </strong>Twelve neonatal series (652 infants) were identified; all but one were single-center and most were retrospective. In referred infants, airway abnormalities were reported in 60-96% and a change in management in 63-94%; when intubated neonates were examined routinely, significant airway disease was found in 19%. The main indications were repeated extubation failure, persistent atelectasis, stridor and suspected congenital anomaly. Transient desaturation occurred in 2-24% of procedures, and one bilateral pneumothorax was reported. Where identified, the operator was usually a pediatric pulmonologist, so the procedure is currently a bedside consultation, not point-of-care testing in the sense applied to ultrasound. No study has examined mortality, bronchopulmonary dysplasia, duration of ventilation or length of stay.</p><p><strong>Conclusions: </strong>Bedside flexible bronchoscopy answers questions about the neonatal airway that ultrasound cannot, and in selected infants it often changes what is done next. Its place should be defined by prospective studies with stated denominators, consistent reporting of physiological cost, and a training pathway for neonatal operators. Reduced exposure to tuberculosis and other hospital pathogens by avoiding transport is a hypothesis, not a demonstrated benefit.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109224"},"PeriodicalIF":3.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216704","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Improving inpatient palliative care delivery in COPD: a mixed-methods study.","authors":"Natalia Smirnova, Tamar Klaiman, Taylor L Stallings, Trishya L Srinivasan, Olivia A Bernal, Joanna L Hart, Dio Kavalieratos, Katherine R Courtright","doi":"10.1016/j.rmed.2026.109217","DOIUrl":"10.1016/j.rmed.2026.109217","url":null,"abstract":"<p><strong>Background: </strong>There is limited evidence to guide implementation of recommended collaborative palliative care (PC) models for hospitalized patients with chronic obstructive pulmonary disease (COPD). We sought to characterize palliative needs and identify barriers to PC delivery to inform inpatient collaborative care models.</p><p><strong>Methods: </strong>We conducted a sequential explanatory mixed-methods study of hospitalized adults with COPD and physicians (hospitalists and pulmonologists) at two urban teaching hospitals in the United States. Patients rated their palliative needs in a survey, followed by a semi-structured interview. Physicians rated the perceived needs of a typical hospitalized patient with moderate-to-severe COPD, and then a purposive sample completed an interview. Survey data were summarized descriptively. Two independent coders conducted content analysis of interview transcripts to identify convergent and divergent perspectives across participant groups.</p><p><strong>Results: </strong>Fifteen patients (mean age 67 years; 47% female, 47% Black, 47% White) and 39 physicians (56% hospitalists, 44% pulmonologists, 44% female, 64% White, 23% Asian) completed surveys. All patients and 15 physicians completed interviews. Participants identified three domains of palliative needs: physical symptoms, psychosocial and emotional distress, and communication. Although physicians rated palliative needs as more burdensome than patients did, they frequently deferred addressing these needs due to competing clinical demands, prognostic uncertainty, and the perceived limited value of inpatient PC consultation. Patients reported that their palliative needs often remained unaddressed.</p><p><strong>Conclusions: </strong>Collaborative inpatient PC models for COPD should prioritize addressing common palliative needs, strengthen generalist PC skills, establish clear criteria for specialist PC involvement, and improve coordination across care settings.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109217"},"PeriodicalIF":3.3,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149216748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of inhaled corticosteroid use with first Pseudomonas aeruginosa isolation in eosinophilic bronchiectasis: a multicenter retrospective study.","authors":"Yawen Wang, Runqing Liu, Xiujuan Bian, Guoqing Zhang, Lili Hou, Jie Ren, Suqin Ben, Jiayue Wu, Rong Tang, Xiaoyan Liu, Ying Ding, Wenjuan Ouyang, Meihua Zhao, Wenping Wang, Jianwei Gao, Ping Shao, Ruomin Liao, Min Zhang, Fengming Ding","doi":"10.1016/j.rmed.2026.109221","DOIUrl":"10.1016/j.rmed.2026.109221","url":null,"abstract":"<p><strong>Background: </strong>The use of inhaled corticosteroids (ICS) in bronchiectasis patients with eosinophilic inflammation is controversial due to the potential risk of bronchial or pulmonary infection. This study examined the association between ICS use and first Pseudomonas aeruginosa isolation across strata of blood eosinophil count (BEC).</p><p><strong>Methods: </strong>A multicenter retrospective study was conducted in patients with bronchiectasis, who were classified according to baseline BEC at cohort entry: HighBEC (≥300 cells/μL), InterBEC (100-299 cells/μL), and LowBEC (<100 cells/μL). ICS use was identified from prescription records, and first P. aeruginosa isolation was defined as the first positive culture for P. aeruginosa from a lower respiratory tract sample after cohort entry. Multivariate Cox proportional hazards regression was used to quantify the risk of first P. aeruginosa isolation associated with ICS use.</p><p><strong>Results: </strong>Of 1900 bronchiectasis patients assessed, 719 were analyzed: 194 (27.0%) received ICS, 525 (73.0%) did not. During follow-up, P. aeruginosa was detected in 69 (9.6%) patients. After adjustment for potential confounders and disease severity indicators, ICS use was associated with a significantly higher risk of first P. aeruginosa isolation in patients with BEC ≥ 100 cells/μL, using no ICS as reference (HighBEC: adjusted HR 4.15, 95% CI 1.29-13.38, P = 0.0172; InterBEC: adjusted HR 3.13, 95% CI 1.56-6.27, P = 0.0013), but not in LowBEC patients (adjusted HR 0.48, 95% CI 0.08-2.79, P = 0.4160). Propensity-matched analyses supported these findings.</p><p><strong>Conclusion: </strong>ICS use was associated with an increased risk of first P. aeruginosa isolation in eosinophilic bronchiectasis, suggesting caution when prescribing ICS to these patients.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109221"},"PeriodicalIF":3.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149207977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and safety of novel nebulized combination of glycopyrronium, formoterol and budesonide in comparison with metered dose inhaler of glycopyrronium, formoterol and budesonide in COPD - A randomized, double-blind, double-dummy clinical trial.","authors":"Rahul Kodgule, Sunil Jagdale, Wen Wu, Rajkumar Nikalje, Maheshkumar Vaghani, Mohammad Hafiz, Akash Balki, Sanjay Khator, Manish Kumar Jain, Amol Pendse, Shabbir Rangwala, Monika Tandon","doi":"10.1016/j.rmed.2026.109220","DOIUrl":"10.1016/j.rmed.2026.109220","url":null,"abstract":"<p><strong>Background: </strong>Many patients with chronic obstructive pulmonary disease (COPD) are unable to use metered dose inhaler (MDI) or dry powder inhaler effectively and require treatment with nebulized medication. No triple combination is available in nebulized form.</p><p><strong>Methods: </strong>In this randomized, double-blind study, 314 patients with COPD received either Glycopyrronium 25 μg/Formoterol Fumarate 20 μg/Budesonide 500 μg (GB/FF/BUD Neb) by nebulization twice daily or Glycopyrronium 7.2 μg, Formoterol Fumarate 5 μg, Budesonide 160 μg MDI (GB/FF/BUD MDI) 2 Puffs twice daily for 12 weeks. The primary endpoint was change from baseline in trough forced expiratory volume in 1 s (FEV₁) at week 12.</p><p><strong>Results: </strong>At week 12, GB/FF/BUD Neb was non-inferior (NI) to GB/FF/BUD MDI in change from baseline in trough FEV₁ [LS mean (SE) difference -0.00 L (95% CI, -0.04 to 0.04); p < 0.001 for NI with NI margin -0.08 L). At week 12, the between group difference was 0.04 L (95% CI: -0.00 to 0.09; p = 0.070) in 2-h post-dose FEV₁ and -0.24 (95% CI: -0.42 to -0.07; p = 0.007) in the modified Medical Research Council (mMRC) dyspnoea score. There was no difference between treatments in the rescue medication use and change from baseline in trough forced vital capacity. No serious adverse event or death was reported. Overall, adverse events were comparable between the two groups.</p><p><strong>Conclusion: </strong>GB/FF/BUD Neb was non-inferior to GB/FF/BUD MDI in improving lung function evaluated by trough FEV₁ in patients with COPD. GB/FF/BUD Neb was found to be safe and well tolerated.</p><p><strong>Clinical trial registration number: </strong>CTRI/2024/10/075606 (Clinical Trial Registry - India).</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109220"},"PeriodicalIF":3.3,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149208000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breathlessness catastrophizing and influencing factors study of elderly COPD patients: A latent profile analysis.","authors":"Chenmeng Wei, Yuye Zhang, Qiufang Li, Xiaokai Wang, Na Song, Tianci Xiao","doi":"10.1016/j.rmed.2026.109219","DOIUrl":"10.1016/j.rmed.2026.109219","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) ranks among the leading global causes of death, with elderly patients facing heightened risks due to age-related declines in lung function. Breathlessness catastrophizing (BC), a negative cognitive response to dyspnea including rumination, magnification. Understanding the heterogeneity of BC in elderly COPD patients is essential for developing targeted interventions.</p><p><strong>Aims: </strong>The objective of this study was to identify subgroups of elderly COPD patients with breathlessness catastrophizing through latent profile analysis (LPA) and to explore the related influencing factors.</p><p><strong>Methods: </strong>The data of 225 elderly patients with COPD were collected and analyzed. The collected data included the demographic and clinical factors, and the patients were assessed with the Breathlessness Catastrophizing Scale(BCS), the COPD Self-Efficacy Scale(CSES) and the Ruminative Response Scale(RRS).</p><p><strong>Results: </strong>The study identified three breathlessness catastrophizing subgroups: Low Breathlessness Catastrophizing Type(44.4%), Moderate Breathlessness Catastrophizing Type(25.8%), and High Breathlessness Catastrophizing Type(29.8%). Three factors were significantly associated with subgroups: number of COPD exacerbations in the past year, COPD self-efficacy, and rumination response (all p < 0.05). Education level and daily steps significantly influenced the low breathlessness catastrophizing type (all p < 0.05).</p><p><strong>Conclusions: </strong>Elderly COPD patients exhibit heterogeneity in breathlessness catastrophizing patterns. Factors including low education levels, frequent acute exacerbations, physical inactivity, diminished self-efficacy, and excessive rumination significantly increase the risk of severe breathlessness catastrophizing. Intervention strategies should prioritize enhancing self-efficacy, managing rumination, promoting physical activity, and implementing personalized approaches for different subgroups with breathlessness catastrophizing. Multidisciplinary collaboration is essential for reducing breathlessness catastrophizing and improving health outcomes.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109219"},"PeriodicalIF":3.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to \"Advancing equity: six-year respiratory outcomes in young Indigenous children following early respiratory disease detection\" [Respir. Med. Volume 262 (2026) 109103].","authors":"Pamela Laird, Isaac Wedderburn, Emily Wray, Zac Dempsey, Mikayla Garstone, Erica Thompson, John Jacky, Matthew Cooper, Sarah Thomason, Myrrhini Coopes, Tiffany Bradshaw, Anne B Chang, André Schultz","doi":"10.1016/j.rmed.2026.109215","DOIUrl":"https://doi.org/10.1016/j.rmed.2026.109215","url":null,"abstract":"","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"109215"},"PeriodicalIF":3.3,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149196113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}